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Chronic fatigue syndrome (CFS) is characterized by alterations of adrenergic cardiovascular 
regulation. We explored the presence of polymorphisms in adrenergic cardiovascular control 
genes in adolescent with CFS, and their relation to cardiovascular variables.  
 
Methods 
DNA from 52 CFS patients were analysed for 5 single nucleotide polymorphisms (SNPs) in 
genes encoding the Catechol-O-methyltransferase (COMT) (rs4680), the 2-adrenergic 
receptor (rs1042713, rs1042714), the 1-adrenergic receptor (rs1801253) and the α2a-
adrenergic receptor (rs1800544). Frequencies were compared to a reference population 
constructed from the NCBI database. Furthermore, associations between autonomic 
cardiovascular responses during a 20
o
 head-up tilt-test and polymorphisms frequencies within 
the patient group were explored.  
 
Results 
For the COMT SNP at rs4680, CFS patients had a higher frequency of the AA genotype 
(Met/Met) and a lower frequency of the G (Val) containing genotypes (AG and GG), as 
compared to the reference sample (p=0.046). Also, among CFS patients, the AA genotype 
was associated with lower diastolic blood pressure (DBP) at baseline (p=0.028) and a smaller 
increase in LF/HF (and index of cardiac sympathovagal balance) during head-up tilt 
(p=0.045) as compared to the AG/GG genotypes. For the rs1042714 SNP in the 2-adrenergic 
receptor gene, CFS patients had a lower frequency of the GG genotype and a higher 
frequency of the genotypes containing C (CG and CC) (p=0.044). No associations to 
cardiovascular variables were found.  
 Conclusion 
Genetic susceptibility to CFS might be related to polymorphisms of COMT and the 2-
adrenergic receptor. The importance of polymorphisms in other adrenergic cardiovascular 
control genes should be explored in further studies.
Introduction 
The Chronic fatigue syndrome (CFS) is a common and disabling disease, characterized by 
severe fatigue and accompanying symptoms such as musculosceletal pain, unrefreshing sleep, 
sore throat, tender lymph nodes, concentration problems and headache (1). The underlying 
disease mechanisms are largely unknown. Previously, we have reported elevated levels of 
epinephrine and norepinephrine at rest among adolescent CFS patients as compared with 
healthy controls (2). Also, as compared to controls, CFS patients had higher blood pressures, 
heart rate and LF/HF ratio (an index of sinus node sympathicovagal balance, derived from 
spectral analyses of heart rate) at rest, and a stronger increase in these variables upon 
orthostatic stress (3, 4, 5). Other studies suggest an association between catecholamine levels 
and CFS symptoms such as fatigue and pain sensitivity (6,7). Taken together, these studies 
indicate enhanced sympathetic nervous activity in CFS, possibly contributing to the 
underlying pathophysiology (8).  
Twin studies indicate a moderate heritability of CFS (9), and molecular analyses 
suggest an association to polymorphisms in genes involved in the metabolism and functioning 
of catecholamines (10). Interestingly, similar associations have been documented in disorders 
having several clinical features in common with CFS, such as the postural orthostatic 
tachycardia syndrome, fibromyalgia and chronic pain syndromes (11, 12, 13, 14). 
Furthermore, genetic polymorphisms are known to influence cardiovascular variables. For 
instance, polymorphisms in the 2-receptor are associated with individual variations in heart 
rate, blood pressure, cardiac output and vasodilatation, in dynamic as well as in resting states 
(11, 15, 16, 17), whereas certain polymorphisms of the 1-receptor are related to vasovagal 
syncope (18). 
The aim of this study was to explore further the possible relation between 
polymorphisms of adrenergic cardiovascular control genes and adolescent CFS. We 
hypothesized that polymorphism frequencies of genes encoding the adrenergic receptor 
proteins α2a, 1, and 2, and the catabolic enzyme Catechol-O-methyltransferase (COMT) 
would be different among CFS adolescents as compared to a reference population. 
Furthermore, we hypothesized an association between these polymorphisms and variables 




Patients with CFS ranging from 11 to 18 years of age were consecutively recruited from the 
paediatric outpatient clinic at Rikshospitalet University Hospital, Oslo, Norway, serving as a 
national referral centre for children and adolescents with unexplained chronic fatigue. Other 
disease states that might explain their present symptoms, such as autoimmune, endocrine, 
neurologic, or psychiatric disorders, were ruled out by a thorough and standardized set of 
investigations. Different case definitions of CFS exist. This study used a slight modification 
of the definition from the Centers for Disease Control and Prevention, in which the main 
criterion is more than 6 months of chronic or relapsing fatigue, severely affecting daily 
activities. In addition, according to this definition, patients should report at least 4 of 8 
specific accompanying symptoms (headache, muscle pain, joint pain, sore throat, tender 
lymph nodes, impaired memory or concentration, unrefreshing sleep, and malaise after 
exertion). However the validity of this definition has been criticized in adults (19, 20) and 
children (21). Participation in this study required only 4 months of chronic or relapsing 
fatigue and no accompanying symptoms. 
One week prior to the experiments, all participants were instructed not to drink 
beverages containing alcohol or caffeine, not to take any drugs, and not to use tobacco 
products. On the day of the experiments, they were requested to fast overnight.  
Written informed consent was obtained from all participants and their parents. The study was 
approved by the Regional committee for ethics in medical research in Norway. 
 
Genotyping  
The NCBI SNP database (22) was used to assign SNP numbers; COMT SNP Rs4680, β2-
receptor SNPs Rs1042714 and Rs1042713, β1-receptor SNP Rs1801253 and alpha2a SNP 
Rs1800544 was selected for testing. Genomic DNA from whole blood cells was extracted 
using DNA isolation kit (E.Z.N.A. Blood DNA kit, Omega Bio-Tek, Inc., Norcross, Georgia, 
USA) and used for 5 exonuclease TaqMan PCR procedure. The genotyping was carried out 
using pre-designed TaqMan assays (Applied Biosystems, Foster City, USA)
 
according to the 
manufacturer's recommendations. Approximately
 
10 ng genomic DNA was amplified in a 5 
µl reaction mixture
 
in a 384-well plate containing 1x universal TaqMan master mix
 
and 1x 
assay mix, the latter containing the respective primers
 
and MGB-probes labeled either with 
FAM or VIC. After initial
 
denaturation and enzyme activation at 95°C for 10 min, the
 
reaction 
mixture was subjected to 40 cycles of 95°C for
 
15 s and 60°C for 1 min. The reactions were 
performed on
 
an ABI 7900HT sequence detection system. Negative controls
 
containing water 
instead of DNA were included in every run.
 
Genotypes were determined using the SDS 2.2 
software (Applied Biosystems, USA). 
 
Reference sample 
A reference sample of the relevant genotypes was constructed from previously reported 
frequencies of European cohort collected from the NCBI SNP database (22). The reference 
frequencies were calculated as a weighted mean of the frequencies reported in the included 
studies. The weighing was done according to number of subjects in each study. In the 
reference sample for the COMT SNP at position rs 4680, four studies were included (23), for 
the β1 receptor SNP at rs 1801253 two studies were included (24), for both the β2-receptor 
SNPs at rs 1042713 and 1042714 three studies were included (25, 26) and one study was 
included in the reference sample for the α2a SNP at Rs 1800544 (27). 
 
Head-up tilt-test  
Head up tilt test (HUT) was performed according to the same protocol as was applied in 
previous CFS studies in our laboratory (3). The subjects lay supine on an electronically 
operated tilt table with foot-board support. They were attached to the Task Force Monitor® 
(Model 3040i, CNSystems Medizintechnik, Graz, Austria), a combined hardware and 
software device for non-invasive recording of cardiovascular variables (28). A 5 minutes 
baseline recording was obtained, after which the subjects were head-up tilted 20
o
 for 15 
minutes. Instantaneous heart rate, arterial blood pressure and stroke volume were obtained 
from the ECG, right middle finger photoplethysmography and thoracic impedance, 
respectively; the latter is not reported in this article.  
 The RR-interval (RRI) from the heart rate recording was subjected to spectral analysis 
using an adaptive autoregressive algorithm, creating a time-varying spectrum (29). Spectral 
power densities (absolute values) were calculated in the low-frequency (LF) band (0.04-0.15 
Hz) and the high-frequency (HF) band (0.15-0.4 Hz); we also calculated the LF/HF ratio. This 
indices are measures of autonomic heart rate control: The HF-variability of RRI is considered 
an index of vagal (parasympathetic) modulation of heart rate, whereas the LF-variability of 
RRI is due to the combined effect of cardiac vagal and sympathetic activity; the LF/HF-ratio 
is a measure of “sympathovagal balance” (30).  
 For each experimental run of HUT, the median of all cardiovascular variables were 
computed in the following epochs: 270 - 30 seconds before tilt (Baseline), and 30 - 270 
seconds after tilt (Tilt). We also computed Δ-values (i.e. Tilt – Baseline).  
 
Statistical analyses  
The statistical analyses were performed using the SPSS (version
 
17.0, Inc, Chicago, IL) 
statistical package and Microsoft Excel for Mac 2008 (version 12.2.3). For each selected SNP, 
genotypic frequencies were dichotomized in CFS patients and the constructed reference 
population, respectively, in order to increase statistical strength. Comparisons between the 
two groups were carried out using chi-square tests. Relations between polymorphisms and 
cardiovascular variables were explored by subgrouping the patients according to genotype, 
and then computing the median of each cardiovascular variable within each genotypic 
subgroup; as some of the cardiovascular variables deviated from a normal distribution, these 
medians were compared using the non-parametric Wilcoxon-Mann-Whitney’s test. A p-value 
of 0.05 was considered statistically significant. Relations between polymorphisms and 
cardiovascular variables were only investigated for the SNPs with CFS genotype frequencies 
differing significantly from the genotype frequencies of the reference population. 
 
Results 
53 patients with CFS were included in the study, 40 % men, 11-18 years of age (Table 1) with 
cardiovascular characteristics as described in table 2. Significant differences in genotype 
frequencies between CFS patients and the reference samples were found for the COMT SNP 
at Rs 4680 and the β2-receptor SNP at rs 1042714 (Table 3). For the COMT SNP at Rs4680, 
the frequency of the AA genotype (Met/Met) was higher and the frequency of the G 
containing genotypes AG (Met/Val) and GG (Val/Val) was lower among CFS patients 
(p=0.046). For the 2-adrenergic receptor SNP at rs1042714, the CFS patients had a higher 
frequency of the heterozygous genotype (CG) and lower frequency of the homozygous 
genotypes compared to the reference sample (p= 0.003). At the same locus the GG genotype 
appeared with a lower, and the C containing genotypes (CG and CC) with a higher frequency 
among the CFS patients as compared to the reference sample (p=0.044). A non-significant 
difference between the CFS patients and the reference sample was also found for the 2-
adrenergic receptor SNP at position Rs 1042713. CFS patients had a higher frequency of the 
GG genotype and a lower frequency of the CG/CC genotypes as compared to the reference 
sample (p=0.079). 
Within the CFS group, the AA genotype of the rs4680 SNP in the COMT gene was 
associated with lower diastolic blood pressure (DBP) at baseline (p=0.028) and a smaller 
increase in LF/HF during tilt (p=0.045) as compared to the AG/GG-variants (Table 4). For the 
rs1042714 SNP in the 2-adrenergic receptor gene, no significant associations between 
genotypes and cardiovascular variables were discovered (Table 5). 
 
Discussion 
The most important finding of this study is the high frequency of the AA genotype of rs4680 
SNP in the COMT gene among CFS patients. COMT has a vital role in the degradation of 
catecholamines such as norepinephrine and epinephrine (31). The A allele encodes a 
substitution of valine to methionine (Val158Met), and those homozygous for this allele 
(met158met carriers) have a 3-to 4-fold reduction in catecholamine degrading enzymatic 
activity as compared to val158val carriers (32, 33). Attenuation of enzyme activity leads to 
higher concentrations of catecholamines, possibly amplifying the effect of sympathetic 
nervous activity. This is perfectly in line with our previous findings of high levels of 
norepinephrine and epinephrine among CFS patients, as well as a tendency towards enhanced 
sympathetic cardiovascular control during orthostatic stress (2,3,4,5). Also, the finding 
confirms results from explorative genetic studies indicating an association between CFS and 
the COMT gene (10). Interestingly, the low-efficiency (COMT) enzyme is also prevalent 
among patients with fibromyalgia, a chronic pain disorder having several clinical features in 
common with CFS (12, 13, 14). Thus, the AA genotype of rs4680 SNP in the COMT gene 
might constitute a genetic predisposition in both CFS and fibromyalgia.  
 Given the functional consequences of the AA genotype (met158met carriers), our 
findings of lower baseline DBP and Δ LF/HF (sympathetic response during tilt) among 
homozygous CFS patients were surprising. However, these results are in line with a recent 
report from Hagen and co-workers documenting that the GG genotype (val158val carriers) is 
associated with higher prevalence of increased systolic blood pressure compared to the AA 
and AG genotypes (34). One possible explanation might be that reduced break-down of 
catecholamines stimulates central inhibitory mechanisms, thus causing an attenuation rather 
than stimulation of sympathetic activity.  
 The CFS patients showed a lower frequency of the GG genotype of the 2-adrenergic 
receptor SNP at rs1042714 (p=0.044) (Table 3). The G allele implies that glutamine is 
replaced by glutamate at amino acid position 27 (26). Several phenotypes have been 
associated with this Gln27Glu polymorphism, but the functional effects remain unclear (35). 
Still, previous investigations suggest that polymorphisms of the 2-adrenergic receptor gene 
are associated with conditions having several clinical features in common with CFS, such as 
temporomandibular disorder (characterized by chronic pain) (15) and the  postural orthostatic 
tachycardia syndrome (POTS) (11), complying with our results. The non-significant 
difference of genotype frequencies found for the 2-adrenergic receptor SNP at rs1042713 
also imply that this receptor could play a role in the pathophysiology of CFS. 
 Taken together, this study suggests that genetic susceptibility to CFS is related to 
polymorphisms of adrenergic cardiovascular control genes, supporting a theory of altered 
sympathetic nervous activity as an important element in the underlying pathophysiology (8). 
Further studies should explore details of the molecular mechanisms, as well as other elements 
of the sympathetic signalling and catabolic system, such as the enzyme monoamine oxidase 
(MAO). As several of these elements are available for pharmacological influence, such 
studies might be of direct clinical relevance.  
 
Study limitations 
The subjects included in the reference population constructed from the NCBI database might 
differ in age and origin from the adolescent CFS population studied. Ideally, a control group 
of healthy adolescents from the same geographic area should have been assembled. 
Furthermore, the CFS population included only 53 subjects, resulting in very low frequencies 
for some genotypes and weakening the statistical power.   
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T a ble  3- G enotype  frequenc ies
R s4680_C OMT 2 (Va l58Met) G G + A G A A No
C F S 31 19 50
C F S  frequenc y 0.62 0.38 1
R eferenc e (NC B I) 114 35 149
R eferenc e frequenc y 0.76 0.24 1
p-value C h s quere tes ti C F S  vs  NC B I 0.046
R s1801253 β1-rec eptor (G ly389Arg , C = Arg , G = G ly) C C + C G G G No
C F S 45 3 48
C F S  frequenc y 0.94 0.06 1
R eferenc e (NC B I) 78 5 83
R eferenc e frequenc y 0.94 0.06 1
p-value C h s quere tes ti C F S  vs  NC B I 0,95
R s1042714 β2-rec eptor (G ln27G lu, C = G ln, G = G ly)C C + C G G G No
C F S 44 7 51
C F S  frequenc y 0.86 0,14 1
R eferenc e (NC B I) 81 25 106
R eferenc e frequenc y 0.72 0.28 1
p-value C h s quere tes ti C F S  vs  NC B I 0.044
R s1042714 β2-rec eptor (G ln27G lu, C = G ln, G = G ly)C G C C + G G No
C F S 30 21 51
C F S  frequenc y 0.59 0.41 1
R eferenc e (NC B I) 45 61 106
R eferenc e frequenc y 0.34 0.66 1
p-value C h s quere tes ti C F S  vs  NC B I 0.003
R s 1042713 β2-rec eptor (Arg 16G ly, A= Arg , G = G ly)G G A G /A A No
C F S 15 33 48
C F S  frequenc y 0.31 0.69 1
R eferenc e (NC B I) 49 57 106
R eferenc e frequenc y 0.46 0.54 1
p-value C h s quere tes ti C F S  vs  NC B I 0.079
R s 1800544 - α2a -rec eptor G G C G + C C No
C F S 3 49 52
C F S  frequenc y 0.06 0.94 1
R eferenc e (NC B I) 0 22 22
R eferenc e frequenc y 0 1 1







HR baseline 72,1 65,4 0,157
Δ2 HR 3,2 3,2 0,626
SBP baseline 109,5 110 0,661
Δ SBP 2,8 2,7 0,922
DBP baseline 68,4 62,4 0,028
Δ DBP 4,3 4,7 0,252
LF-RRI baseline 516 731 0,495
Δ LF-RRI -35 -92 0,367
HF-RRI baseline 670 1143 0,232
Δ HF-RRI -107 -270 0,071
LF/HF baseline 0,72 0,72 0,591
Δ LF/HF 0,27 0,09 0,045
1)Catecholamine-methyl-transferase (COMT)
2)change in the variable during head-up-tilt (Δ)







HR baseline 71,1 62,7 0,427
Δ 1HR 3,1 3,5 0,380
SBP baseline 109,6 107,4 0,380
Δ SBP 2,1 3,1 0,269
DBP baseline 66,8 68,5 0,813
Δ DBP 4,0 5,6 0,269
LF-RRI baseline 646 651 0,967
Δ LF-RRI -98 111 0,350
HF-RRI baseline 906 1525 0,513
Δ HF-RRI -245 -215 0,835
LF/HF baseline 0,73 0,43 0,335
Δ LF/HF 0,19 0,37 0,989
1)Change in the variable during head-up-tilt (Δ)
Table 5  Physiological variables and genotypes the β-
adrenerg receptor rs1042713
 
 
